30 results about "Cholesterol synthesis" patented technology

The invention discloses a sweet potato vine-sourced polypeptide ST2b and application thereof, and belongs to the technical field of biological medicine, the amino acid sequence of the sweet potato vine-sourced polypeptide ST2b is GSFKMEGKR, and the polypeptide ST2b inhibits the occurrence and development of type 2 diabetes mellitus by regulating host cholesterol metabolism, so that the development of type 2 diabetes mellitus is inhibited. Experiments prove that the polypeptide ST2b treatment can inhibit expression of cholesterol synthesis related genes in a host body, so that the cholesterol level in the host body is reduced, and the characteristic of resisting type 2 diabetes mellitus is exerted; the invention provides a novel application for preparing the medicine for the type 2 diabetes mellitus.

The application discloses application of a cholesterol synthesis enzyme in preparation of a product for enhancing killing function of CAR-T cells and derivatives thereof, wherein the cholesterol synthesis enzyme is SQLE or LSS, and the product enhances the killing function by separately knocking out SQLE or separately overexpressing LSS in the CAR-T cells and the derivatives thereof. The application significantly enhances the killing ability of the CAR-T cells and the derivatives thereof by knocking out a key enzyme SQLE in cholesterol synthesis or overexpressing LSS.

Disclosed in the invention are a type of compounds having activity of activating 5′-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

The invention provides a blood fat-reducing ganoderma lucidum spore powder pharmaceutical composition as well as a preparation method and application thereof, and belongs to the technical field of medicines. Comprising a ganoderma lucidum spore powder extract and a pharmaceutical composition, and the mass ratio of the ganoderma lucidum spore powder extract to the pharmaceutical composition is 10: (1-2); the pharmaceutical composition contains a simvastatin derivative and an apatamuron derivative. The prepared blood-fat-reducing ganoderma lucidum spore powder pharmaceutical composition adopts a mixed preparation of traditional Chinese medicine components and western medicine components, has complementary advantages, can quickly reduce cholesterol content and take effect quickly on one hand, can fundamentally inhibit cholesterol synthesis and improve metabolic disorder of hyperlipidemia on the other hand, and is small in side effect, high in patient compliance, good in effect and free of toxic and side effects on the other hand. Certain anti-inflammatory, anti-thrombotic and anti-tumor effects and the like are achieved, and the application prospect is wide.

The invention belongs to the field of gene editing, and particularly relates to a method for regulating milk fat content. The expression of genes in fatty acid and cholesterol synthesis pathways of the livers of the animals in the lactation period is specifically regulated and controlled through a gene delivery technology, the expression of liver apolipoprotein B (ApoB) and the triglyceride and total cholesterol level in blood can be remarkably reduced, then the lipid content of milk is effectively reduced, meanwhile, the food intake of the animals is reduced, and the production cost is reduced. And the milk protein content is not influenced. According to the method, milk fat components are accurately controlled through maternal liver gene editing for the first time, a new strategy is provided for breeding healthy dairy animals, and the method has wide application prospects.

This invention discloses a chemical-biological fusion method for cholesterol synthesis. Using plant-derived 21-hydroxy-20-methylpregn-4-en-3-one, also known as bis(2-hydroxy-2-yl)-3-one (BA), as a raw material, cholesterol is synthesized through a four-step reaction involving sulfonation, acetylation, enzymatic hydrolysis and reduction, and Grignard coupling. Addressing the drawbacks of traditional animal-derived cholesterol, which carries unpredictable risks of pathogenic bacteria and viruses, this invention uses plant-derived steroidal raw material BA to synthesize cholesterol. This method not only offers high safety, avoiding the risk of pathogenic bacteria and viral infections, but also utilizes the tandem catalysis of esterase and carbonyl reductase during synthesis, along with coenzyme regeneration, to obtain key intermediates with high stereoselectivity and in a safe and clean manner. This significantly shortens the cholesterol synthesis route, increases efficiency, simplifies operation, minimizes solvent recycling losses, reduces waste, and allows for mild reaction conditions. This method is safe, economical, and suitable for industrial production.

The present application relates to the field of organic synthesis, in particular to a kind of method for catalytic hydrogenation of cholesterols to synthesize dihydrocholesterol, with cholesterols as raw material, hydrogen donor, Pd / CuO-Al2O3 Catalyst occurs hydrogenation and generates dihydrocholesterol, the present application avoids directly using hydrogen as raw material, safety is good, meets the trend of green chemical industry, and reaction condition is mild, reaction temperature is low, reaction time is short, with good industrial production application prospect.

This invention discloses a genetically engineered strain of *Saccharomyces cerevisiae* and its application in cholesterol synthesis. The strain was obtained through multiple genetic engineering steps, starting with *Saccharomyces cerevisiae* SquP1: DHCR24 gene was integrated at the YPL062W site to achieve 7-dehydrocholesterol synthesis; the ERG6 promoter was replaced with the ERG7 promoter and the DWF5 gene was integrated to achieve cholesterol synthesis; the TGL3, TGL4, and ROX1 genes were knocked out to enhance cholesterol accumulation; the FLX1 and ZWF1 genes were integrated to strengthen cofactor supply; the HXK1 promoter was replaced and the ERG11 gene was integrated to optimize the synthesis pathway; and auxotrophic genes were reintroduced to obtain the CC37N strain. This strain achieved a maximum yield of 6.23 g / L in a 5L bioreactor fermentation, providing an excellent strain for efficient cholesterol biosynthesis.

The invention is suitable for the technical field of traditional Chinese medicine, and provides a traditional Chinese medicine preparation for treating AIDS combined with hyperlipidemia and a preparation method thereof.The preparation is prepared from 10-20 parts of red yeast rice, 20-30 parts of lotus leaves, 10-20 parts of raw bighead atractylodes rhizome, 8-15 parts of fortune eupatorium herb, 8-15 parts of semen raphani, 8-15 parts of semen cassiae, 20-30 parts of raw radix astragali, 20-30 parts of fiveleaf gynostemma herb, 8-15 parts of rhizoma curcumae longae, 10-20 parts of raw oyster shell and 6-12 parts of rhodiola rosea. The monascus purpureus inhibits cholesterol synthesis by natural statins, the lotus leaves promote lipid metabolism and inhibit fat absorption, and the monascus purpureus and the lotus leaves are monarch drugs and have a remarkable lipid-lowering effect. Raw atractylodes macrocephala, eupatorium fortunei and the like are used as ministerial drugs and closely cooperate with monarch drugs, so that the effects of lowering lipid and dissolving turbidity are further enhanced. According to the theory of traditional Chinese medicine, the prescription aims at the pathogenesis of'deficiency in root and excess in superficies and intermingled phlegm and blood stasis' of AIDS (acquired immune deficiency syndrome) combined with hyperlipemia, warmth and clearness are applied simultaneously, tonifying and relieving are taken into consideration, both symptoms and root causes are treated, and a brand new treatment

The application discloses simvastatin-beta-cyclodextrin nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines, wherein the simvastatin-beta-cyclodextrin conjugate has active oxygen responsiveness, comprises an ester bond connection structure formed by a beta-cyclodextrin hydroxyl group, a thio-ketone connection unit and a simvastatin hydroxyl group, and the thio-ketone connection unit is a thio-ketone dicarboxylic acid residue formed by condensation of 3-mercaptopropionic acid and acetone; the simvastatin-beta-cyclodextrin conjugate can self-assemble to form simvastatin-beta-cyclodextrin nanoparticles. The active oxygen responsive simvastatin-beta-cyclodextrin conjugate provided by the application can dissociate in an oxidative stress related environment, realizes double-path cholesterol homeostasis regulation functions of inhibiting cholesterol synthesis and promoting cholesterol efflux, reduces the degree of macrophage foam, and further reduces the lipid load of an atherosclerotic plaque.

The application discloses a traditional Chinese medicine composition with lipid-lowering efficacy, Quling Huatu granules and a preparation method thereof, and belongs to the technical field of Chinese patent medicines. The traditional Chinese medicine composition comprises the following components in parts by weight: 5-10 parts of red yeast rice, 10-30 parts of poria cocos, 5-15 parts of atractylodes, 5-15 parts of dried ginger and 5-15 parts of costus. The atractylodes, the poria cocos and the costus in the application can dispel cold, invigorate the spleen, warm the middle and harmonize the stomach, so that the qi of the spleen and stomach runs smoothly. Meanwhile, the Quling Huatu granules contain statin components, can inhibit the synthesis of excessive cholesterol in the body, increase the synthesis of low-density protein receptors, reduce the blood cholesterol and low-density protein cholesterol levels, prevent the further development of cardiovascular diseases, and also do not cause problems such as liver and kidney function damage and gastrointestinal discomfort.

The invention discloses a Pinellinoic acid derivative shown in a general formula (I) (the specific substituent definition is shown in the specification), a pharmaceutical composition with the Pinellinoic acid derivative as an active component, a preparation method of the compound and application of the Pinellinoic acid derivative in preparation of drugs for inhibiting cholesterol synthesis activity and drugs for treating non-alcoholic fatty liver diseases. Belongs to the technical field of medicines. Pharmacological test results indicate that the Songlinolenic acid derivative has good sterol ester de novo synthesis and fatty acid de novo synthesis inhibitory activity. The compound can be used as a novel high-efficiency sterol lipid synthesis inhibitor, can be used for treating diseases related to sterol lipid metabolism, and has a good application prospect.

The present invention relates to the field of biotechnology, specifically to the immune effects and uses of farnesyl diphosphate, an intermediate metabolite of cholesterol synthesis. The present invention relates to the use of farnesyl diphosphate or its analogs, derivatives, potentiators, or inhibitors in regulating dendritic cell chemotaxis and / or lymphocyte activation, or in the preparation of a drug or kit for regulating dendritic cell chemotaxis and / or lymphocyte activation, as well as corresponding drugs or kits and methods of regulation. The present invention can be applied to regulating dendritic cell chemotaxis and / or lymphocyte activation, and / or further used to regulate the body's immune response and homeostasis, prevent and treat allergic diseases such as allergic rhinitis, autoimmune diseases such as systemic lupus erythematosus, and select tumor immunotherapy regimens and / or prognosis assessment, and has broad application prospects.

The invention discloses targeted prebiotic plant extraction dietary powder for conditioning hyperlipidemia and a preparation process of the targeted prebiotic plant extraction dietary powder. In the invention, patent strains such as lactobacillus plantarum LP-12, bifidobacterium longum BL-08 and the like in the formula can regulate intestinal flora balance and inhibit activity of liver cholesterol synthesis key enzymes, so that generation of endogenous cholesterol is reduced from the source; natural monacolin K and phytosterol ester in the red yeast rice powder respectively inhibit cholesterol synthesis and competitively block exogenous cholesterol absorption to form a bidirectional regulation mechanism. Meanwhile, the oat beta-glucan forms an adhesive layer in the intestinal tract, so that part of lipid absorption is physically blocked; and prebiotics such as resistant dextrin and fructo-oligosaccharide provide nutrients for probiotics, promote secretion of short-chain fatty acids and further activate lipid metabolism related pathways. The components cooperate with one another to cover the whole chain of cholesterol synthesis, absorption and metabolism, so that the multi-dimensional lipid-lowering effect of'source inhibition-process blocking-metabolic regulation 'is realized.

This invention relates to a composition of ellagic acid and terbinafine and its application in the preparation of drugs for treating bladder cancer, belonging to the field of biomedical technology. To address the problem that terbinafine treatment of bladder cancer easily causes compensatory increases in SQLE expression levels, this invention provides a composition of ellagic acid and terbinafine, consisting of ellagic acid and terbinafine in a mass ratio of 5:8. This invention uses this composition in the preparation of drugs for treating bladder cancer. Terbinafine can directly inhibit SQLE enzyme activity, blocking cholesterol synthesis and inhibiting tumor growth, while ellagic acid can reduce the compensatory upregulation of SQLE expression caused by terbinafine alone. The synergistic effect of the two can reduce the metabolic side effects caused by terbinafine and the drug toxicity of ellagic acid, significantly enhancing the anti-bladder cancer effect and overcoming monotherapy resistance. This invention is based on the development of already marketed drugs, possessing the dual advantages of therapeutic enhancement and improved safety, providing a more optimized treatment plan for bladder cancer.

The invention belongs to the technical field of microorganisms, and in particular relates to lactobacillus helveticus IOB726 with an effect of reducing blood fat as well as a segmented fermentation preparation method and application of the lactobacillus helveticus IOB726. The invention discovers that the lactobacillus helveticus IOB726 has the effect of reducing blood fat for the first time. The lactobacillus helveticus IOB726 bacterial powder and the preparation thereof are prepared by adopting segmented liquid state fermentation for the first time, not only is the bacterial activity improved, but also an inulin component is added into a second-stage fermentation culture medium, so that a carbon source is provided for the growth of the lactobacillus helveticus IOB726, and the lactobacillus helveticus IOB726 is promoted to generate short-chain fatty acid in the fermentation metabolism process; the liver cholesterol synthesis can be inhibited, so that the hyperlipemia symptom can be improved. Besides, experimental results show that the lactobacillus helveticus IOB726 has an efficient blood fat reducing effect, has good acid resistance, bile salt resistance and gastrointestinal tract simulation tolerance, can play a role in human intestinal tracts, supplements strain resources of blood fat reducing probiotics, and shows a better blood fat reducing effect.

This invention discloses a genetically engineered strain of *Kluyveromyces martensii* and its applications, belonging to the field of bioengineering technology. The invention discloses a genetically engineered *Kluyveromyces martensii* strain, firstly obtained through screening a strain that produces high levels of ergosterol; based on this, it induces and isolates... Eye A haploid strain was constructed and then metabolically optimized through the introduction of heterologous DHCR24 and DWF5 genes, weakening of the competitive pathway gene ERG6, increasing the metabolic flux of the post-squalene pathway during sterol synthesis, peroxisome compartmentalization engineering of the mevalonate pathway, knockout of the hypoxia-inhibiting transcription factor ROX1, improved cofactor supply, and optimization of the yeast lipid pathway, resulting in a high-cholesterol-producing engineered strain. Through fed-batch fermentation, efficient and stable cholesterol synthesis was achieved, with a yield of 7.64 g / L, laying the foundation for cholesterol biomanufacturing.

The invention relates to the technical field of biological medicines, in particular to a medicine for synchronously improving polycystic ovarian syndrome hyperandrogenemia and lipid metabolism disorder, which takes a specific anti-ACBP neutralizing antibody as an active ingredient and plays a role by blocking two key pathological pathways mediated by ACBP: 1, blocking the interaction between ACBP and a transcription factor SREBP2 / HNF-4alpha, and 2, blocking a transcription factor SREBP2 / HNF-4alpha; the expression of a cholesterol synthesis rate-limiting enzyme HMGCR / HMGCS1 is down-regulated, and androgen synthesis substrates are reduced from the source; and secondly, the interaction between ACBP and mitochondrial transport protein TSPO / StAR is blocked, and the transport of cholesterol into mitochondria is inhibited, so that the generation of testosterone is reduced. The medicine can synchronously and remarkably reduce the serum testosterone level of a PCOS model animal, improve the polycystic form of an ovary and reduce the body weight, total cholesterol and low-density lipoprotein (LDL) level.

The invention discloses an application of cholesterol synthetase in preparation of a product for enhancing the killing function of CAR-T cells and derivatives thereof, the cholesterol synthetase is SQLE or LSS, and the product enhances the killing function by separately knocking out the SQLE or separately overexpressing the LSS in the CAR-T cells and the derivatives thereof. According to the application, a cholesterol synthesis key enzyme SQLE is knocked out or LSS is overexpressed, so that the killing ability of CAR-T cells and derivatives thereof is remarkably enhanced.

The invention relates to the technical field of organic synthetic chemistry, in particular to a method for synthesizing 7-dehydrocholesterol from cholesterol. Comprising the following steps: dissolving cholesterol in a first solvent, adding cyclohexanone and aluminum isopropoxide, and carrying out an Oppenauer oxidation reaction to obtain an intermediate 1; dissolving the intermediate 1 in a second solvent, sequentially adding isopropenyl acetate and p-toluenesulfonic acid, and carrying out first acetylation reaction to obtain an intermediate 2; dissolving the intermediate 2 in a third solvent, and carrying out an upper debromination reaction to obtain an intermediate 3; and dissolving the intermediate 3 in a fourth solvent, then adding 2, 4, 6-trimethylpyridine and acetyl chloride as reaction accelerators, carrying out a second acetylation reaction to obtain an intermediate 4, and carrying out a reduction reaction and purification on the intermediate 4 to obtain the 7-dehydrocholesterol. The 7-dehydrocholesterol is synthesized by the method, the total synthesis yield exceeds 60%, the product purity is 98% or above, and the method is easy to amplify for industrial synthesis.

The invention relates to an ellagic acid and terbinafine composition and application thereof to preparation of a medicine for treating bladder cancer, and belongs to the technical field of biological medicine. The invention provides an ellagic acid and terbinafine composition which is used for solving the problem that the compensation of SQLE expression level is easily increased when terbinafine is used for treating bladder cancer, and the ellagic acid and terbinafine composition is prepared from ellagic acid and terbinafine in a mass ratio of 5: 8. The application is used for preparing the bladder cancer treatment medicine, terbinafine can directly inhibit SQLE enzyme activity, block cholesterol synthesis and inhibit tumor growth, ellagic acid can reduce SQLE expression compensatory up-regulation caused by independent treatment of terbinafine, metabolic side effects caused by terbinafine and medicine toxicity of ellagic acid can be reduced through synergism of terbinafine and ellagic acid, and the bladder cancer treatment medicine can be used for treating bladder cancer. The bladder cancer resisting effect is obviously enhanced, and the single drug resistance is overcome. Based on the development of medicines on the market, the traditional Chinese medicine composition has the double advantages of treatment synergy and safety improvement, and a more optimized treatment scheme is provided for bladder cancer treatment.

The invention discloses preparation and application of a novel lipid-lowering drug of a liver targeting specific antibody-statin conjugate in the technical field of biological pharmacy, and the preparation method comprises the following steps: step 1, synthesizing a linker which comprises a response molecule and an invariant molecule, and connecting the response molecule and the invariant molecule through acylation reaction of acyl chloride and hydroxyl; step 2, synthesizing a prodrug by using a connexon and a drug molecule, wherein the connexon and the drug molecule are connected through an esterification reaction; and step 3, combining the prodrug with the monoclonal antibody, and connecting the maleimide with the cysteine residue of the monoclonal antibody through Click reaction. The anti-PCSK9 monoclonal antibody and the statins are coupled through the responsive connexon, targeted delivery of the statins and responsive drug release are achieved, the antibody and the drugs act synchronously, endogenous cholesterol synthesis is reduced while the liver cholesterol removing capacity is improved, the effects of double-effect driving and efficient lipid lowering are achieved, and the application prospect is wide. The lipid-lowering curative effect and the medication compliance of a patient are improved.

The invention relates to the field of organic synthesis, in particular to a method for synthesizing dihydrocholesterol by catalytically hydrogenating cholesterol, cholesterol is used as a raw material, hydrogenation reaction is performed in the presence of a hydrogen donor and a Pd / CuO-Al2O3 catalyst to generate dihydrocholesterol, direct use of hydrogen as the raw material is avoided, safety is good, the green chemical industry trend is met, reaction conditions are mild, and the method is suitable for industrial production. The reaction temperature is low, the reaction time is short, and the industrial production application prospect is good.

The invention discloses a construction method and application of a fetal-derived hypercholesterolemia animal model. The fetal-derived hypercholesteremia animal model is characterized in that 20 mg / kg of aspirin with a clinical dose is given to rodents (such as Kunming mice) through oral intragastric administration in the middle and late pregnancy periods (such as 9-18 pregnancy), and typical hypercholesteremia appears after high-fat diet is given to male filial generations 8-12 weeks after the male filial generations are born. Based on mice exposed by aspirin during pregnancy, ascorbic acid is externally supplemented to maternal bodies during pregnancy, so that the liver cholesterol synthesis function and the blood cholesterol level of offspring can be effectively reduced. Therefore, the established fetal hypercholesterolemia animal model has the characteristics of novelty, reliability and simplicity and convenience in operation, meanwhile, the effect of reversing the susceptibility of offspring hypercholesterolemia by supplementing ascorbic acid to the maternal body is found, and a new thought and a new technology are provided for early prevention and treatment of fetal hypercholesterolemia.

Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

The application belongs to the technical field of cosmetics, and discloses an anti-wrinkle composition, a preparation method and application thereof. The composition comprises the following components: mevalonolactone, hydroxytyrosol, guaiacol sulfonate sodium and betaine. The application utilizes the superior antioxidant performance of hydroxytyrosol, combines mevalonolactone which can promote the synthesis of cholesterol, and guaiacol sulfonate sodium which has excellent anti-inflammatory effect, controls from multiple aspects of free radical elimination, cholesterol synthesis to maintain skin elasticity, and inhibition of the release of inflammatory factors and inflammatory mediators, and simultaneously cooperates with betaine which is easy to penetrate and has a calming effect. Through compounding the four components, the synergistic effect can be exerted, so that excellent anti-inflammatory, wrinkle-removing and anti-aging effects can be achieved.

The present invention has been made in view of the conventional demand for clear elucidation of the mechanism of action as to whether or not the total cholesterol amount in the plasma and liver is reduced, and the present invention produces inhibitors containing 3, 5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient, and provides inhibitors that exhibit an excellent effect of acting on HMGCR via SREBP2 and suppressing and inhibiting the cholesterol synthesis pathway itself.SOLUTION: The present invention is characterized by containing 3, 5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient, which acts on HMGCR via SREBP2 to suppress and inhibit the cholesterol synthesis pathway.SELECTED DRAWING: Figure 1

[Problem] The present invention has been made in response to the need to elucidate the mechanism of action underlying a previously confirmed reduction in plasma and liver total cholesterol levels. The present invention relates to producing and providing an inhibitor that contains 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient and is highly effective for directly suppressing and inhibiting a cholesterol synthesis pathway by acting on HMGCR via SREBP2. [Solution] The present invention is characterized by having suppressive and inhibitory effects on a cholesterol synthesis pathway on the basis of the action of 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient on HMGCR via SREBP2.

The invention relates to an application of a signal regulation method based on non-classical Hippo in diseases caused by RIPK4 inactivation mutation. YAP / TAZ is activated in a manner of knocking out RIPK4, phenotypes of diseases caused by RIPK4 inactivation mutation are successfully simulated, expression or activity of YAP / TAZ is respectively inhibited in a manner of knocking down, knocking out YAP / TAZ or overexpressing RIPK4, and drugs for treating or relieving diseases caused by RIPK4 inactivation mutation are developed by aiming at inhibiting YAP / TAZ gene expression or activity. In addition, abnormal expression of a group of cholesterol synthesis genes (Fdft1, Mvd, Cyp51 and Nsdhl) is found; therefore, YAP / TAZ with deregulated activity and cholesterol synthesis genes with abnormal expression can be used as diagnostic markers, and the YAP / TAZ gene can also be used as a therapeutic target.